BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Orexo Interim Report Q3 2017

  Financial overview Q3 2017 Total net revenues SEK 166.2M Zubsolv U.S. net revenue SEK 121.1M.

  October 19, 2017

   · 

  5 min read
• Business

  Quotient Clinical Signs Agreement With Nuformix to Evaluate Cocrystal Formulations Using Translational Pharmaceutics

  Under the deal, Quotient will use its Translational Pharmaceutics platform to develop a formulated oral NXP001 cocrystal product and validate its performance in healthy subjects.

  October 19, 2017

   · 

  2 min read
• Business

  Danaher Reports Third Quarter 2017 Results

  Danaher today announced results for the third quarter of 2017.

  October 19, 2017

   · 

  29 min read
• FDA

  BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy

  BioLife Solutions today announced that its customer Kite Pharma has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

  October 19, 2017

   · 

  3 min read
• Business

  Teleflex Announces Third Quarter 2017 Earnings Conference Call Information

  Teleflex announced today that financial results for the third quarter 2017 will be released before market open on Thursday, November 2, 2017.

  October 19, 2017

   · 

  1 min read
• Business

  Quest Diagnostics Reports Third Quarter 2017 Financial Results, Updates 2017 Financial Guidance and Reaffirms Long Term Outlook

  Quest Diagnostics announced today financial results for the third quarter ended September 30, 2017.

  October 19, 2017

   · 

  58 min read
• Biotech Bay

  Imprimis to Offer Compounded Cyclosporine Alternative to Restasis

  Imprimis today announced it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable and potentially lower-cost alternatives to Restasis.

  October 19, 2017

   · 

  5 min read
• 

  FDA

  FDA Clears Kent Imaging’s Multispectral Medical Imaging Device (KD203)

  Kent’s device is the next step in perfusion imaging by directly showing tissue oxygenation.

  October 19, 2017

   · 

  1 min read
• Drug Development

  AOBiome Therapeutics Reports Positive Efficacy Results from Phase IIb Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

  AOBiome today announced positive efficacy and safety findings from the Phase 2b clinical trial of the Company’s Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of mild-to-moderate acne vulgaris.

  October 19, 2017

   · 

  4 min read
• Business

  PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results

  PTC Therapeutics today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company’s business and outlook on Thursday, November 2, 2017 at 4:30 p.m. (ET) after the closing of the market.

  October 19, 2017

   · 

  1 min read